Literature DB >> 18573828

Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis.

A Javed1, R Balabanov, B G W Arnason, T J Kelly, N J Sweiss, P Pytel, R Walsh, E A Blair, A Stemer, M Lazzaro, A T Reder.   

Abstract

Devic's disease is often considered as a variant of multiple sclerosis (MS). However, evidence suggests that Devic's disease may be distinct from MS. Devic's disease can coexist with connective tissue diseases, particularly Sjögren's disease, but this association is rare with MS. Diagnosis of Sjögren's disease in patients with neurological symptoms is often difficult. During early stages of Sjögren's disease, patients may not fulfill all criteria for Sjögren's disease. A high percentage of patients with Sjögren's disease have inflammatory infiltrates in minor salivary glands, and this may be a reliable indicator of early or subclinical disease. We show high prevalence (80%) of salivary gland inflammation in Devic's disease and longitudinally extensive transverse myelitis (LETM). We diagnosed 16 patients with Devic's disease, and 2 of these satisfied criteria for Sjögren's disease as did 2 of 9 patients with LETM. Anti-SSA/B titers were infrequently elevated. Although most did not satisfy criteria for Sjögren's disease. 9 of 12 Devic's disease patients and 7 of 8 LETM patients had severe salivary gland inflammation. Thus: (1) patients with Devic's disease or with LETM who have positive labial biopsies but do not satisfy criteria for Sjögren's disease could have subclinical Sjögren's diseases. Alternatively, (2) as patients with Devic's disease have elevated titers of several autoantibodies, so there may exist a set of antibodies that react with antigens in minor salivary glands and cause inflammation. Minor salivary gland biopsy is more sensitive than anti-SSA/B serology in providing histological evidence for possible Sjögren's disease with CNS lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573828     DOI: 10.1177/1352458508088941

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

Review 1.  Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.

Authors:  Eduardo Freitas; Joana Guimarães
Journal:  Rheumatol Int       Date:  2014-06-22       Impact factor: 2.631

2.  Neuromyelitis optica - an update: 2007-2009.

Authors:  Anu Jacob
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

3.  Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis.

Authors:  Xuan Feng; Nicholas P Reder; Mounica Yanamandala; Addie Hill; Beverly S Franek; Timothy B Niewold; Anthony T Reder; Adil Javed
Journal:  J Neurol Sci       Date:  2011-10-27       Impact factor: 3.181

Review 4.  Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist.

Authors:  Roberto A Cruz; Sana Chaudhary; Myriam Guevara; Ethan Meltzer
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 5.  Vasculitis in Sjögren's Syndrome.

Authors:  R Hal Scofield
Journal:  Curr Rheumatol Rep       Date:  2011-12       Impact factor: 4.592

6.  Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis.

Authors:  Hongyang Li; Yanling Wang; Quangang Xu; Aidi Zhang; Huanfen Zhou; Shuo Zhao; Hao Kang; Chunxia Peng; Shanshan Cao; Shihui Wei
Journal:  J Neurol       Date:  2015-07-11       Impact factor: 4.849

7.  Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.

Authors:  Zhihua Ren; Yan Wang; Tao Duan; Jilpa Patel; Thomas Liggett; Eileah Loda; Sarang Brahma; Rajendra Goswami; Carrie Grouse; Richard Byrne; Dusan Stefoski; Adil Javed; Stephen D Miller; Roumen Balabanov
Journal:  J Immunol       Date:  2012-09-24       Impact factor: 5.422

Review 8.  How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.

Authors:  Anthony T Reder; Xuan Feng
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

Review 9.  Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology.

Authors:  Anthony T Reder; Xuan Feng
Journal:  Front Immunol       Date:  2013-09-17       Impact factor: 7.561

10.  Neurologic Complications Associated with Sjögren's Disease: Case Reports and Modern Pathogenic Dilemma.

Authors:  Michele Colaci; Giulia Cassone; Andreina Manfredi; Marco Sebastiani; Dilia Giuggioli; Clodoveo Ferri
Journal:  Case Rep Neurol Med       Date:  2014-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.